FR940606-2-00055 FR940606-2-00039 Food and Drug Administration [Docket No. 94N&hyph;0195] Adria Laboratories, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 15 abbreviated new drug applications (ANDA's). The holders of the ANDA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. EFFECTIVE DATE: July 6, 1994. FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD&hyph;360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1038. SUPPLEMENTARY INFORMATION: The holders of the ANDA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing. 1ANDA no. 1Drug 1Applicant 17&hyph;959 Fluorouracil Injection, U.S.P., 50 milligrams (mg)/milliliter (mL) Adria Laboratories, P.O. Box 16529, Columbus, OH 43216&hyph;6529. 18&hyph;419 Furosemide Tablets, U.S.P., 20 mg, 40 mg, and 80 mg Warner Chilcott Laboratories, 201 Tabor Rd., Morris Plain, NJ 07950. 18&hyph;420 Furosemide Injection, U.S.P., 10 mg/mL i0Do. 18&hyph;670 Furosemide Injection, U.S.P., 10 mg/mL Wyeth-Ayerst Laboratories, P.O. Box 8299, Philadelphia, PA 19101&hyph;1245. 18&hyph;690 Indomethacin Capsules, U.S.P., 25 mg and 50 mg Chelsea Laboratories, Inc., 896 Orlando Ave., West Hempstead, NY 11552. 19&hyph;106 Hydrocortisone Butyrate Ointment 0.1% Galderma Laboratories, Inc., 3000 Alta Mesa Blvd., suite 300, P.O. Box 331329, Fort Worth, TX 76163. 72&hyph;398 Sulfamethoxazole and Trimethoprim Oral Suspension, U.S.P., 200 mg/40 mg per 5 mL Barre-National, Inc., 333 Cassell Dr., suite 3500, Baltimore, MD 21224. 85&hyph;191 Hydrocortisone Cream, U.S.P., 1% Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960. 85&hyph;214 Sterile Hydrocortisone, Acetate Suspension, U.S.P., 50 mg/mL Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043&hyph;4705. 86&hyph;001 Theophylline Syrup, 80&hyph;2 mg/15 mL Barre-National, Inc. 87&hyph;161 Dipyridamole Tablets, U.S.P., 75 mg Chelsea Laboratories, Inc. 88&hyph;449 Fluocinolone Acetonide, Topical Solution, U.S.P., 0.01% Pharmafair, Inc., 110 Kennedy Dr., Hauppauge, NY 11788. 88&hyph;475 Glycopyrrolate Injection, U.S.P., 0.2 mg/mL Fujisawa USA, Inc., Parkway North Center, Three Parkway North, Deerfield, IL 60015&hyph;2548. 88&hyph;606 Acetic Acid 2% and Aluminum Acetate Otic Solution Pharmafair, Inc. 89&hyph;223 Theophylline Elixir, 80 mg/15 mL Barre-National, Inc. Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the ANDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective July 6, 1994. Dated: May 24, 1994. Murray M. Lumpkin, Acting Director, Center for Drug Evaluation and Research. [FR Doc. 94&hyph;13711 Filed 6&hyph;3&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
